With the safe distancing and circuit breaker measures in place, companies and corporations in Singapore are experiencing increasing difficulties when conducting general meetings for shareholders.
Businesses and individuals around the world have been affected by unprecedented and unforeseeable supply chain disruptions, manpower shortages and cashflow issues arising from the COVID-19 pandemic. In his speech on the COVID-19 (Temporary Measures) Bill, Law Minister K. Shanmugam noted the increasing difficulties of businesses and individuals in fulfilling their contractual obligations due to the COVID-19 outbreak. To complement the financial schemes, grants and reliefs announced by the Singapore Government in the Resilience Budget and Solidarity Budget on 26 March 2020 and 6 April 2020, the COVID-19 (Temporary Measures) Act 2020 (“Act”) was passed on 7 April 2020.
Through the three budgets as announced by the Singapore Government, a total of S$9 billion will be disbursed to businesses and individuals in April 2020 to counter the impact that the COVID-19 pandemic has had on the business community in Singapore. Businesses and workers in Singapore will receive reliefs through various measures announced by the Singapore Government in the Solidarity Budget and Reliance Budget, through the enhanced Wage Credit Scheme, Foreign Workers Levy, and the Jobs Support Scheme.
How does the new Intellectual Property Dispute Resolution Bill alter the landscape for IP disputes in Singapore across all areas of IP?
SIAC has published a proposal on cooperation between arbitral institutions to allow the consolidation of related arbitrations being conducted under the rules of different institutions.
For years, defendants in patent infringement proceedings have brought counterclaims for revocation of the patent. However, a recent High Court judgment indicates that this is no longer possible.
On 1 August 2017, the Singapore Court of Appeal in Warner-Lambert Company LLC v Novartis (Singapore) Pte Ltd  SGCA 45 dismissed Warner-Lambert’s application to amend its patent for the use of pregabalin for the treatment of pain (the “Patent”).
The Singapore Government and the Intellectual Property Office of Singapore (IPOS) have announced proposed changes to Singapore’s patents regime which they are seeking public feedback on until 1 August 2017.
As Singapore strives to keep its environment conducive for businesses, the Ministry of Finance of Singapore and the Accounting and Corporate Regulatory Authority (“ACRA”) conducted a second review on the Companies Act, not long after changes to the Companies Act were implemented in two phases on 1 July 2015 and 3 January 2016, respectively.